Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRAF | P15056 | 5/20 | 0.54 |
| ▸ | EGFR | P00533 | 10/20 | 0.46 |
| ▸ | IGF1R | P08069 | 10/20 | 0.44 |
| ▸ | ERBB2 | P04626 | 9/20 | 0.44 |
| ▸ | LCK | P06239 | 4/20 | 0.42 |
| ▸ | KDR | P35968 | 4/20 | 0.42 |
| ▸ | MAP4K4 | O95819 | 3/20 | 0.42 |
| ▸ | MAP4K2 | Q12851 | 3/20 | 0.42 |
| ▸ | STK3 | Q13188 | 3/20 | 0.42 |
| ▸ | AURKB | Q96GD4 | 3/20 | 0.42 |
| ▸ | MAP4K5 | Q9Y4K4 | 3/20 | 0.42 |
| ▸ | PRKD3 | O94806 | 2/20 | 0.42 |
| ▸ | FYN | P06241 | 2/20 | 0.42 |
| ▸ | CSF1R | P07333 | 2/20 | 0.42 |
| ▸ | RET | P07949 | 2/20 | 0.42 |
| ▸ | TAOK1 | Q7L7X3 | 2/20 | 0.42 |
| ▸ | AURKA | O14965 | 1/20 | 0.42 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.42 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.42 |
| ▸ | INSR | P06213 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2746248 | 0.92 | BRAF (0.48) | BRAFEGFRIGF1RERBB2LCK | |
| SCHEMBL2745807 | 0.88 | BRAF (0.53) | BRAFPTK2 | |
| SCHEMBL3811056 | 0.87 | BRAF (0.70) | BRAFEGFRIGF1RERBB2MAP4K4 | |
| SCHEMBL2754169 | 0.84 | BRAF (0.49) | BRAFEGFRIGF1RERBB2LCK | |
| SCHEMBL3808570 | 0.83 | BRAF (0.60) | BRAFEGFRIGF1RERBB2FGFR1 | |
| SCHEMBL2745888 | 0.83 | BRAF (0.56) | BRAFEGFRIGF1RERBB2LCK | |
| SCHEMBL3814527 | 0.83 | BRAF (0.57) | BRAFFGFR1MAP3K20ABL1PTK2 | |
| SCHEMBL3809247 | 0.82 | BRAF (0.55) | BRAFEGFRIGF1RERBB2FGFR1 | |
| SCHEMBL2746204 | 0.82 | EGFR (0.49) | BRAFEGFRIGF1RERBB2LCK | |
| SCHEMBL2746307 | 0.82 | BRAF (0.49) | BRAFMAP4K4AURKBPRKD3TAOK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8178672-B2 | Synthesis of imidazooxazole and imidazothiazole inhibitors of p38 MAP kinase | ARQULE, INC. (US) | 2012-05-15 | — | — | US | disclosed |
| US-8178672-B2 | Synthesis of imidazooxazole and imidazothiazole inhibitors of p38 MAP kinase | ARQULE, INC. (US) | 2012-05-15 | — | — | US | disclosed |
| US-8178672-B2 | Synthesis of imidazooxazole and imidazothiazole inhibitors of p38 MAP kinase | ARQULE, INC. (US) | 2012-05-15 | — | — | US | disclosed |
| EP-2258704-A1 | Synthesis of imidazooxazole and imidazothiazole inhibitors of p38 map kinase | ArQule, Inc. (US) | 2010-12-08 | — | — | EP | disclosed |
| US-20090136499-A1 | RAF Inhibitors and Uses Thereof | ARQULE, INC. (US) | 2009-05-28 | — | — | US | disclosed |
| US-20090136499-A1 | RAF Inhibitors and Uses Thereof | ARQULE, INC. (US) | 2009-05-28 | — | — | US | disclosed |
| US-20090136499-A1 | RAF Inhibitors and Uses Thereof | ARQULE, INC. (US) | 2009-05-28 | — | — | US | disclosed |
| US-20090111985-A1 | Synthesis of imidazooxazole and imidazothiazole inhibitors of p38 map kinase | ARQULE, INC. | 2009-04-30 | — | — | US | disclosed |
| US-20090111985-A1 | Synthesis of imidazooxazole and imidazothiazole inhibitors of p38 map kinase | ARQULE, INC. | 2009-04-30 | — | — | US | disclosed |
| US-20090111985-A1 | Synthesis of imidazooxazole and imidazothiazole inhibitors of p38 map kinase | ARQULE, INC. | 2009-04-30 | — | — | US | disclosed |
| US-7501430-B2 | e.g. 3-{5-[2-({(3R)-1-[(4-chlorophenyl)sulfonyl]piperidin-3-yl}amino)pyrimidin-4-yl]imidazo[2,1-b][1,3]thiazol-6-yl}phenyl carbamate; antiproliferative, anticarcinogenic agent; cell proliferative disorders | ARQULE, INC. (US) | 2009-03-10 | — | — | US | disclosed |
| US-7501430-B2 | e.g. 3-{5-[2-({(3R)-1-[(4-chlorophenyl)sulfonyl]piperidin-3-yl}amino)pyrimidin-4-yl]imidazo[2,1-b][1,3]thiazol-6-yl}phenyl carbamate; antiproliferative, anticarcinogenic agent; cell proliferative disorders | ARQULE, INC. (US) | 2009-03-10 | — | — | US | disclosed |
| US-7501430-B2 | e.g. 3-{5-[2-({(3R)-1-[(4-chlorophenyl)sulfonyl]piperidin-3-yl}amino)pyrimidin-4-yl]imidazo[2,1-b][1,3]thiazol-6-yl}phenyl carbamate; antiproliferative, anticarcinogenic agent; cell proliferative disorders | ARQULE, INC. (US) | 2009-03-10 | — | — | US | disclosed |
| US-20070281955-A1 | RAF inhibitors and their uses | ARQULE, INC. | 2007-12-06 | — | — | US | disclosed |
| US-20070281955-A1 | RAF inhibitors and their uses | ARQULE, INC. | 2007-12-06 | — | — | US | disclosed |
| US-20070281955-A1 | RAF inhibitors and their uses | ARQULE, INC. | 2007-12-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070281955-A1 | RAF inhibitors and their uses | BRAF, RAF1, ARAF | BRAF 1/4885EGFR 271/4885IGF1R 859/4885 |
| US-20090111985-A1 | Synthesis of imidazooxazole and imidazothiazole inhibitors of p38 map kinase | MAPK1, MAPK14, MAPK15 | BRAF 181/4885EGFR 3374/4885IGF1R 1336/4885 |
| US-20090136499-A1 | RAF Inhibitors and Uses Thereof | BRAF, RAF1, ARAF | BRAF 1/4885EGFR 306/4885IGF1R 916/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.